Psychedelics Weekly – Cannabis as an Adjunct Cancer Treatment & 5-MeO-DMT Reactivations

December 2, 2022
Featuring: Joe Moore & Alexa Jesse

Subscribe Share

In this week’s episode, Joe and Alexa talk about the excitement brewing around our first conference-meets-festival, Convergence (March 30 – April 2 at the Wisdome in LA), and some of the sponsorships starting to come in (interested? email

Then, they dive into what intrigued them the most this week: a study looking into potentiality and possible causes of 5-MeO-DMT reactivation (and what reactivation actually is); New York cannabis farms sitting on $750 million worth of cannabis as the government drags its feet on licenses; and the story of a woman who used cannabis and psilocybin as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer.


Convergence (Use code PTINSIDER10 for 10% off!) (Use code SHROOM for 30% off)

Psychedelics Today 236 – Drugs: Honesty, Responsibility, and Logic, featuring: Dr. Carl Hart

Psychedelics Today 268 – PCP, 5-MeO-DMT, and The Synthesis of New Psychedelics, featuring: Hamilton Morris Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence

YouTube: Norm Macdonald talks LSD

Psychedelics Today: HPPD and Flashbacks: Everything You Need To Know – And What We Don’t Know, Too New York Cannabis Farms Have $750 Million of Weed — and Nowhere to Sell It

Grace Health & Wellness Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer Researcher Charles Nichols Studies the Impact of Psychedelic Substances on Inflammation What Is Right To Try? The cannabis nurse hotline

Joe Moore (1)-min

In this Episode

Joe Moore

Co-Founder & CEO

Alexa Jesse-min

Alexa Jesse

Director of Sales and Strategic Partnerships